Ratings Zai Lab Limited

Equities

ZLAB

US98887Q1040

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
17.78 ^USD	-2.25%		-0.78%	-34.94%

05-24	Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	MT
05-22	Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ZAI LAB LIMITED	-34.94%	1.76B	B
CSL LIMITED	-2.29%	89.87B	A-
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B	A-
UCB	+63.05%	26.47B	A
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B	C
INCYTE CORPORATION	-7.96%	12.99B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B	B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B	B+
INNOVENT BIOLOGICS, INC.	-17.66%	7.32B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes